Failure to report previously used drugs and dosages in pharmaceutical company-sponsored rheumatoid arthritis trials: Comment on the article by Yocum et al
Open Access
- 9 September 2004
- journal article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 50 (9) , 3051
- https://doi.org/10.1002/art.20642
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: A double‐blind trialArthritis & Rheumatism, 2003
- Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imagingArthritis & Rheumatism, 2002
- Guidelines for the management of rheumatoid arthritis: 2002 UpdateArthritis & Rheumatism, 2002
- Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexateArthritis & Rheumatism, 2001
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and MethotrexateArchives of internal medicine (1960), 1999